Literature DB >> 15799845

[PREVENCAT study: control of cardiovascular risk in primary care].

Luis A Alvarez-Sala1, Carmen Suárez, Teresa Mantilla, Josep Franch, Luis M Ruilope, José R Banegas, Vivencio Barrios.   

Abstract

BACKGROUND AND
OBJECTIVE: Most studies of cardiovascular risk factors (CVRF) conducted in our environment concentrate in a single CVRF. The PREVENCAT study was designed to estimate the control of CVRF in the population attended in primary care presenting arterial hypertension (HT), type 2 diabetes mellitus (DM2) and/or hypercholesterolemia (HC) as well as to assess the prevalence of Metabolic Syndrome in these patients. PATIENTS AND
METHOD: Multicenter, cross-sectional study, in patients with HT, DM2 and/or HC, consecutively recruited by primary care physicians in Spain. The blood pressure, cholesterol, basal glycaemia, obesity, smoking and physical activity were assessed. The degree of control of these CVRF and the prevalence of MS were estimated.
RESULTS: 2,649 patients were recruited, aged 64 (11.3) years, with a 51.6% of women. The most frequent diagnosis was HT (78.9%), followed by HC (58.4%) and DM2 (37.4%). In the whole sample, the percentages of patients who had a control or had initially normal values of blood pressure, cholesterol and basal glycemia were 40.0% (confidence interval [CI], 95% 38.2-41.9), 42.6% (95% CI, 40.5-44.7) and 62.7% (95% CI, 60.8-64.5), respectively. 15.6% of cases (95% CI, 14.3-17.0) had body mass index < or = 25 kg/m2; 87.5% were non-current smokers (95% CI, 86.2-88.8); and 46.2% practiced regular physical activity (95% CI, 44.3-48.1). 40% of patients had < or = 2 CVRF in good control. The prevalence of metabolic syndrome was 50.6% (95% CI, 48.7-52.5).
CONCLUSIONS: The control of the CVRF considered in primary care attended population is insufficient. Hardly one of each 2 patients with HT, DM2 and HC is under control. The overweight and sedentarism control is still poorer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15799845     DOI: 10.1157/13072841

Source DB:  PubMed          Journal:  Med Clin (Barc)        ISSN: 0025-7753            Impact factor:   1.725


  13 in total

1.  [Cardiovascular risk in Spanish smokers compared to non-smokers: RETRATOS study].

Authors:  Jaime Fernández de Bobadilla; Verónica Sanz de Burgoa; Patricio Garrido Morales; Esteban López de Sá
Journal:  Aten Primaria       Date:  2011-03-21       Impact factor: 1.137

2.  [Lifestyles of subjects who take drugs for two or more cardiovascular risk factors. TAR-RISC Study].

Authors:  Josep Carles Llop Margalef; Silvia Hernández Anadón; Josep Bítria Ibars; Albert Josa; José María Crespo; Ferran Bejarano Romero; Carles Llor
Journal:  Aten Primaria       Date:  2010-05-20       Impact factor: 1.137

3.  [Cardiovascular risk factors: a follow up study in a non-diabetic population].

Authors:  María Vernet Vernet; María José Sender Palacios; Esther Jovell Fernández; Encarnació Tor Figueras; Ramón Casals Riera; Pere Larrosa Sàez
Journal:  Aten Primaria       Date:  2009-08-06       Impact factor: 1.137

4.  [European Guidelines on Cardiovascular Disease Prevention in Clinical Practice. CEIPC 2008 Spanish Adaptation].

Authors:  José M A Lobos Bejarano; Miguel Angel Royo-Bordonada; Carlos Brotons; Luís Alvarez-Sala; Pedro Armario; Antonio Maiques; Dídac Mauricio; Susana Sans; Fernando Villar; Angel Lizcano; Antonio Gil-Núñez; Fernando de Alvaro; Pedro Conthe; Emilio Luengo; Alfonso Del Río; Olga Cortés; Ana de Santiago; Miguel A Vargas; Mercedes Martínez; Vicenta Lizarbe
Journal:  Aten Primaria       Date:  2009-07-15       Impact factor: 1.137

5.  [Durability of the effects of a quality improvement intervention in hypertensive patients on long-term follow-up (CICLO-RISK study)].

Authors:  Manuel Angel Gómez Marcos; Emiliano Rodríguez Sánchez; Emilio Ramos Delgado; Carmen Fernández Alonso; Angel Luis Montejo Gónzalez; Luis García Ortiz
Journal:  Aten Primaria       Date:  2009-05-15       Impact factor: 1.137

6.  [Improved effectiveness in the management of cardiovascular risk among type 2 diabetic patients in primary health care].

Authors:  Antonio Hormigo Pozo; María Angeles Viciana López; Leonor Gómez Jiménez; María Dolores Gallego Parrilla; Javier Orellana Lozano; José Miguel Morales Asencio
Journal:  Aten Primaria       Date:  2009-04-08       Impact factor: 1.137

7.  Plant sterol-enriched fermented milk enhances the attainment of LDL-cholesterol goal in hypercholesterolemic subjects.

Authors:  Nuria Plana; Catherine Nicolle; Raimon Ferre; Jordi Camps; Rosa Cos; Jesus Villoria; Luis Masana
Journal:  Eur J Nutr       Date:  2008-01-14       Impact factor: 5.614

8.  Effectiveness of a combined strategy to improve therapeutic compliance and degree of control among patients with hypercholesterolaemia: a randomised clinical trial.

Authors:  Ignacio Párraga-Martínez; Joseba Rabanales-Sotos; Fernando Lago-Deibe; Juan M Téllez-Lapeira; Francisco Escobar-Rabadán; Alejandro Villena-Ferrer; Mariano Blasco-Valle; José M Ferreras-Amez; Susana Morena-Rayo; José M del Campo-del Campo; Maria Candelaria Ayuso-Raya; José J Pérez-Pascual
Journal:  BMC Cardiovasc Disord       Date:  2015-01-19       Impact factor: 2.298

9.  Metabolic syndrome as a cardiovascular disease risk factor: patients evaluated in primary care.

Authors:  Joan-Josep Cabré; Francisco Martín; Bernardo Costa; Josep L Piñol; Josep L Llor; Yolanda Ortega; Josep Basora; Marta Baldrich; Rosa Solà; Jordi Daniel; Josep Ma Hernández; Judit Saumell; Jordi Bladé; Ramon Sagarra; Teresa Basora; Dolors Montañés; Joan L Frigola; Angel Donado-Mazarrón; Maria Teresa García-Vidal; Isabel Sánchez-Oro; Josep M de Magriñà; Ana Urbaneja; Francisco Barrio; Jesús Vizcaíno; Josep M Sabaté; Irene Pascual; Vanesa Revuelta
Journal:  BMC Public Health       Date:  2008-07-22       Impact factor: 3.295

10.  Blood pressure and lipid goal attainment in the hypertensive population in the primary care setting in Spain.

Authors:  Vivencio Barrios; Carlos Escobar; Alberto Calderón; José L Llisterri; Rocio Echarri; Eduardo Alegría; Javier Muñiz; Arantxa Matalí
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-05       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.